Last edition
News about
ModeX Therapeutics Doses First Patients in Trial of Novel Tetraspecific Therapy for B-Cell Lymphoma
ModeX Therapeutics initiates clinical testing of MDX2003, a next-generation multispecific antibody therapy designed to enhance immune response and improve outcomes in B-cell lymphoma patients.
ImmunoForge Unveils LMT15 Platform to Transform CNS Drug Delivery
The clinical-stage biotech firm ImmunoForge is advancing its next-generation blood-brain barrier shuttle technology, combining enhanced brain permeability with long-acting formulations to accelerate therapies for CNS and rare diseases.
Biology-Led Economy to Power India's Rise by 2047: Jitendra Singh
Addressing a conference at Indian Institute of Technology Roorkee, Jitendra Singh said India’s bio-economy could reach USD 1 trillion by 2047, driven by innovation, biotech growth and policy reforms.
Atrium Therapeutics receives a USD 15 million milestone payment from Bristol Myers Squibb under a global collaboration to develop innovative RNA-based therapies for cardiovascular diseases.
AbbVie Provides US Regulatory Update on TrenibotE BLA
AbbVie gets US FDA Complete Response Letter (CRL) for TrenibotE BLA tied to manufacturing processes; no new clinical studies needed.
Nektar Therapeutics Closes USD 373.8 Million Public Offering
Nektar Therapeutics completes USD 373.8 million public offering, including full exercise of underwriters’ option to purchase additional shares.
US FDA Approves Sanofi's Tzield to Delay Type 1 Diabetes Progression in Children
Sanofi’s Tzield gains US FDA approval to delay stage-III Type 1 Diabetes in children aged one year and above, the first disease-modifying therapy for stage-II T1D.
Australia Approves MINJUVI (tafasitamab) for Relapsed or Refractory Follicular Lymphoma
Australia approves MINJUVI (tafasitamab) with rituximab and lenalidomide, the first chemo-free dual-targeted therapy for relapsed follicular lymphoma.
Mabwell Launches Phase 3 Trial of Nectin-4 ADC 9MW2821 for Triple-Negative Breast Cancer
Mabwell launches Phase 3 study of 9MW2821, the world’s first Nectin-4 ADC for TNBC, marking its fourth pivotal clinical trial.
WuXi Biologics Secures South Korea GMP Certification for Key Manufacturing Facilities
The South Korea GMP Certification from the Ministry of Food and Drug Safety strengthens WuXi Biologics’ end-to-end capabilities for commercial production of complex biologics, including cancer therapies.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy